Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis

Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis

Primary myelofibrosis (PMF) is a clonal stem cell disease, characterized by bone marrow fibrosis. Ruxolitinib is a selective inhibitor of JAK-1 and JAK-2 used to treat PMF. Its mechanism of action is based on the reduction of signal transduction and cytokine levels; including IL-6 and tumor necrosi...

Full description

Saved in:
Bibliographic Details
Main Authors: Mehmet S Pepeler, Zübeyde N Özkurt, Özlem T Güzel, Nalan Akyürek
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2018-10-01
Series:Journal of Infection in Developing Countries
Subjects:
Primary myelofibrosis
ruxolutinib
tuberculosis
infection
JAK-2 inhibitor
Online Access:https://jidc.org/index.php/journal/article/view/9993
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jidc.org/index.php/journal/article/view/9993

Similar Items